|
|
This article was retracted on May 15, 1999.
 Previous Article | Table of Contents | Next Article 
Interleukin-4 inhibits growth of multiple myelomas by suppressing
interleukin-6 expression
F Herrmann, M Andreeff, HJ Gruss, MA Brach, M Lubbert and R Mertelsmann
Department of Hematology and Oncology, University of Freiburg Medical
Center, Germany.
Unfractionated bone marrow (BM) cells obtained from patients with multiple
myeloma (MM) exhibit high levels of interleukin (IL)-6. Secretion of IL-6
by these cells as well as spontaneous plasma cell proliferation can be
abrogated by neutralizing anti-IL-6 monoclonal antibody (MoAb). Treatment
of BM cells with recombinant human (rh)IL-4 at doses of 50 to 250 U/mL
blocked endogenous IL-6 synthesis in a dose- dependent fashion and was
associated with significant reduction of plasma cell growth that could be
reversed by exogenous rhIL-6. Enrichment of BM cells from MM patients for
plasma cells and adherent cells and analysis of IL-6 mRNA in these
subpopulations by means of quantitative polymerase chain reaction (PCR)
showed that adherent BM cells accounted for most of the synthesis of IL-6
transcripts, whereas plasma cells displayed negligible levels of IL-6 mRNA
only. These results suggest therapeutic evaluation of rhIL-4 in patients
with plasma cell neoplasms.
Volume 78,
Issue 8,
pp. 2070-2074,
10/15/1991
Copyright © 1991 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. Tassone, P. Neri, R. Burger, R. Savino, M. Shammas, L. Catley, K. Podar, D. Chauhan, S. Masciari, A. Gozzini, et al.
Combination Therapy with Interleukin-6 Receptor Superantagonist Sant7 and Dexamethasone Induces Antitumor Effects in a Novel SCID-hu In vivo Model of Human Multiple Myeloma
Clin. Cancer Res.,
June 1, 2005;
11(11):
4251 - 4258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Retraction of several recent papers from Dr. Friedhelm Herrmann's laboratories.
Blood,
May 15, 1999;
93(10):
3573 - 3573.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. V. Dhodapkar, E. Abe, A. Theus, M. Lacy, J. K. Langford, B. Barlogie, and R. D. Sanderson
Syndecan-1 Is a Multifunctional Regulator of Myeloma Pathobiology: Control of Tumor Cell Survival, Growth, and Bone Cell Differentiation
Blood,
April 15, 1998;
91(8):
2679 - 2688.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hallek, P. Leif Bergsagel, and K. C. Anderson
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Blood,
January 1, 1998;
91(1):
3 - 21.
[Full Text]
[PDF]
|
|
|
|
|
